Dysregulated expression of the tumor suppressor p14ARF in cancer provides an effective target for TCR-T cell therapeutics
These findings demonstrate the feasibility of targeting dysregulated tumor suppressor proteins with TCR-T cell therapeutics and identify p14ARF as a promising target for future therapies.
Authors
- Kavya Rakhra (ORCID: https://orcid.org/0000-0003-2371-0470)
- Jennifer S. Michaelson (ORCID: https://orcid.org/0009-0005-4539-460X)
- Angie Vazquez
- Naveen K. Mehta
- Patrick A. Baeuerle (ORCID: https://orcid.org/0009-0006-7117-2784)
- Jennifer Lam (ORCID: https://orcid.org/0000-0002-3130-5515)
- Cheryl Black
- Kelsey Furiya
- Menna Hailemariam
- Kerry A. Whalen (ORCID: https://orcid.org/0000-0001-8003-0346)
- Lam Trieu
- Aude G. Chapuis
- Jaishree Sharma
- Thomas M Schmitt
- Bo Lee
- Daniel H Paushter
- Philip D Greenberg
Institutions
- University of Washington (US)
- Fred Hutch Cancer Center (US)
- C4 Therapeutics (United States) (US)
Publication Details
- Journal
- Journal for ImmunoTherapy of Cancer
- Published
- 2026-02-01
- DOI
- https://doi.org/10.1136/jitc-2025-013520
- Primary Topic
- Protein Degradation and Inhibitors
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Fred Hutchinson Cancer Research Center
- Parker Institute for Cancer Immunotherapy